Abstract
Sequestering of latent HIV in follicular helper T cells within B-cell follicles that largely exclude cytotoxic T cells is a major barrier to cellular immune-based approaches to eradicate HIV. Here, we show that the clinical-grade human interleukin-15 (IL-15) superagonist ALT-803 activates and redirects simian immunodeficiency virus (SIV)-specific CD81 T cells from the peripheral blood into B-cell follicles. In agreement with the increased trafficking of SIVspecific cytotoxic T cells to sites of cryptic viral replication, lymph nodes of elite controlling macaques contained fewer cells expressing SIV RNA or harboring SIV DNA post-ALT-803 treatment. These data establish ALT-803 as an immunotherapeutic for HIV and other chronic viral pathogens that evade host immunity by persisting in B-cell follicles.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 76-84 |
| Number of pages | 9 |
| Journal | Blood Advances |
| Volume | 2 |
| Issue number | 2 |
| DOIs | |
| State | Published - Jan 23 2018 |
Bibliographical note
Publisher Copyright:© 2018 by The American Society of Hematology.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'The human IL-15 superagonist ALT-803 directs SIV-specific CD8+ T cells into B-cell follicles'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS